Summit Therapeutics Inc. (SMMT) is a pioneering biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines to treat rare diseases and infectious diseases, particularly those for which no effective therapies currently exist. This dedication to finding and developing newer ways to address lesser explored but impactful health challenges makes Summit a unique entity in the pharmaceutical industry.
Concentrated mainly in two areas, Duchenne Muscular Dystrophy and Clostridioides difficile infection (CDI), Summit is empowering lives by bringing innovation and transforming treatment approaches for these severe conditions. Duchenne Muscular Dystrophy is a fatal genetic disease that causes muscle degeneration and premature death, usually in the early twenties. Summit is working on a potentially transformative therapy that could treat the underlying genetic cause and modify the disease course. In the case of C. difficile infections, Summit is developing a novel class of antibiotics that aims to safely eradicate the initial infection and protect against recurrent disease, a considerable challenge with this infection.
Headquartered in Cambridge, Massachusetts, Summit Therapeutics was incorporated in 2003. The company has strived to foster a culture of inclusivity and excellence, creating an environment for bright-minded scientists and professionals' capability to push the boundaries of medical understanding and patient care. The nature of Summit’s work is challenging, painstaking, and hugely significant, as it is driven by vast unmet medical needs that demand relentless scientific exploration and patient-centered commitment.
Working in close collaboration with world-leading institutions, Summit utilizes its unique platform technology and intelligence to deliver potentially life-changing therapies. The company works in a business model that emphasizes partnerships and collaborations that leverage its innovative technologies to develop superior pharmaceutical products.
Summit Therapeutics Inc. is publicly traded on the NASDAQ Stock Market under the ticker symbol "SMMT." Over the years, it has shown dedication through its innovative research and the development of novel, candidate drugs. Though the road to success in the pharmaceutical industry is long and requires considerable resources, Summit appears committed to its mission of bringing transformative medicines to patients suffering from rare and infectious diseases. The company's work speaks to the hope and promise of biotechnology - the concept of using our understanding of nature at the molecular level to solve some of humanity's most profound health challenges.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Summit Therapeutics presented updated overall survival (OS) data for ivonescimab in EGFR-mutated non-small cell lung cancer (NSCLC) from its HARMONi Phase III trial at the IASLC World Conference on Lung Cancer. Ivonescimab, a bispecific antibody targeting PD-1 and VEGF, is being tested in patients who progressed on a third-generation EGFR TKI. While progression-free survival (PFS) improvements have been reported, the full OS dataset is crucial for determining regulatory submission viability and will be key to understanding whether the OS benefit is persuasive or requires longer follow-up.
Summit Therapeutics' shares increased after Jefferies upgraded the stock and revised its price target. This upgrade comes amidst several recent positive developments for Summit Therapeutics, including positive topline results from a Phase III study for ivonescimab in biliary tract cancer and China approval for ivonescimab in NSCLC. The biopharmaceutical company is focused on developing patient-friendly medicinal therapies.
Summit Therapeutics (SMMT) shares rose 5.8% in premarket trading after Jefferies upgraded the stock to Buy from Hold and increased its price target to $25 from $15. The upgrade is based on anticipated positive progression-free survival data from the company's H3 study for ivonescimab, expected later in 2026, and the potential for overall survival benefits in 2027. Jefferies analysts are confident in ivonescimab's efficacy, citing previous positive results and its first-in-class positioning.
Summit Therapeutics (SMMT) experienced a 28.19% share price surge following positive results from clinical trials for its bispecific antibody, ivonescimab. Its partner, Akeso Inc., reported significant overall survival improvements in non-small cell lung cancer patients, as well as superiority in treating advanced biliary tract cancer when combined with chemotherapy. These results strengthen the potential for ivonescimab across various cancer indications, though regulatory approval and commercial success are not yet guaranteed.
Summit Therapeutics (SMMT) shares rose after Bernstein SocGen upgraded the biotechnology company from Underperform to Market Perform, raising its price target to $11.90. The upgrade reflects a more appropriate valuation of ivonescimab, the company's late-stage drug candidate, acknowledging the recent reset in its share price. Despite reservations about ivonescimab's potential to replace Keytruda broadly, the firm noted positive broader market conditions and ongoing regulatory review as supportive factors.
Summit Therapeutics (SMMT) recently announced positive topline results from its Phase III HARMONi-GI1 trial for an advanced biliary tract cancer treatment, which was conducted in collaboration with Akeso. Despite a high Price-to-Sales ratio and ongoing unprofitability, the market anticipates substantial future growth driven by its promising clinical pipeline. The company's GF Score is low at 30/100, but significant insider purchases indicate strong internal confidence.
Summit Therapeutics (NASDAQ:SMMT), a clinical-stage biotechnology company, is gaining renewed attention due to updates on its development pipeline and market activities. The company focuses on precision medicines, particularly its leading oncology candidate, ivonescimab, and also has a diversified research approach including infectious diseases. Its future direction is closely tied to clinical progress, regulatory developments, and expanding its research programs, such as evaluating ivonescimab across multiple cancer types.
HC Wainwright has reissued a "Neutral" rating for Summit Therapeutics (NASDAQ:SMMT), aligning with the analyst consensus of "Hold" and an average target price of $24.25. The company's shares are trading near their 52-week low at $12.63, and it reported a quarterly EPS of ($0.28), slightly below estimates. Notably, corporate insiders have significantly increased their holdings, purchasing 7.87 million shares valued at approximately $103.6 million in the last 90 days.
Summit Therapeutics (NASDAQ:SMMT) shares recently hit a new 52-week low, trading at approximately $12.20, below both their 50-day and 200-day moving averages. This drop follows lowered analyst price targets, a consensus "Hold" rating, and the company narrowly missing quarterly earnings estimates with a loss of $0.28 per share. Despite the stock's decline, company insiders have shown strong confidence, purchasing 7.87 million shares worth about $103.6 million in the last quarter, bringing their collective ownership to 83.5%.
Dimensional Fund Advisors LP significantly reduced its stake in Summit Therapeutics PLC by 76.5% in the first quarter, selling over 288,000 shares. Despite this, Summit Therapeutics has seen strong insider buying, with executives acquiring 7.87 million shares worth approximately $103.6 million in the past three months. The company's stock opened down 7.3% at $14.00, and analysts currently have a consensus "Hold" rating with a target price of $24.25, following a missed EPS estimate.